|
||
|
||
|
History CreoSalus was originally founded as Thorn Bioscience LLC by Mrs. Laura Thorn in 1995. Its original and continuing mission is to develop novel peptide-based veterinary drugs for use in reproductive management, therapeutics, and vaccines of domestic animals. These products are a continuation of work initiated by Thornbrook Farm's New York Reproductive Research and Development Laboratory, an international leader in equine reproductive research in its own right and by virtue of its support of research at leading universities. In 1998, the ownership of the company was expanded to include approximately 70 individual investors. Together with Mrs. Torn, these investors represent the foundation of the company's current ownership. In May of 2005, Thorn Bioscience acquired ACT Holdings and Thuramed Devices. ACT Holdings held, as its primary interest, the assets of Advanced ChemTech, a peptide building blocks, scale-up and custom synthesis company. Thuramed Devices held, as its primary assets, substantial intellectual property in cardiology, women's health and peptide synthesizer technology. In June of 2005, the parent company was renamed CreoSalus, Inc. which comes from the Latin "to create good health". Today CreoSalus is organized into three synergistic divisions based entirely on peptide science. Thorn Bioscience (www.thornbioscience.com) has two peptide-based veterinary drugs in the final stages of FDA approval and it offers a wide range of GMP synthesis and formulation services. Advanced ChemTech (www.advancedchemtech.com) offers peptide building blocks, scale-up services and custom synthesis. Thuramed (www.thuramed.com) offers proprietary state-of-the-art peptide synthesizers. We serve thousands of customers worldwide. All of our facilities are located in Louisville, KY and we are committed to US manufacturing to ensure the quality and traceability that our customers demand.  |
||
